» Articles » PMID: 38256243

Isolated Valve Amyloid Deposition in Aortic Stenosis: Potential Clinical and Pathophysiological Relevance

Abstract

Amyloid deposition within stenotic aortic valves (AVs) also appears frequent in the absence of cardiac amyloidosis, but its clinical and pathophysiological relevance has not been investigated. We will elucidate the rate of isolated AV amyloid deposition and its potential clinical and pathophysiological significance in aortic stenosis (AS). In 130 patients without systemic and/or cardiac amyloidosis, we collected the explanted AVs during cardiac surgery: 57 patients with calcific AS and 73 patients with AV insufficiency (41 with AV sclerosis and 32 without, who were used as controls). Amyloid deposition was found in 21 AS valves (37%), 4 sclerotic AVs (10%), and none of the controls. Patients with and without isolated AV amyloid deposition had similar clinical and echocardiographic characteristics and survival rates. Isolated AV amyloid deposition was associated with higher degrees of AV fibrosis ( = 0.0082) and calcification ( < 0.0001). Immunohistochemistry analysis suggested serum amyloid A1 (SAA1), in addition to transthyretin (TTR), as the protein possibly involved in AV amyloid deposition. Circulating SAA1 levels were within the normal range in all groups, and no difference was observed in AS patients with and without AV amyloid deposition. In vitro, AV interstitial cells (VICs) were stimulated with interleukin (IL)-1β which induced increased SAA1-mRNA both in the control VICs (+6.4 ± 0.5, = 0.02) and the AS VICs (+7.6 ± 0.5, = 0.008). In conclusion, isolated AV amyloid deposition is frequent in the context of AS, but it does not appear to have potential clinical relevance. Conversely, amyloid deposition within AV leaflets, probably promoted by local inflammation, could play a role in AS pathophysiology.

Citing Articles

Novel Insights into Non-Invasive Diagnostic Techniques for Cardiac Amyloidosis: A Critical Review.

Dicorato M, Basile P, Muscogiuri G, Carella M, Naccarati M, Dentamaro I Diagnostics (Basel). 2024; 14(19).

PMID: 39410653 PMC: 11475987. DOI: 10.3390/diagnostics14192249.


Myocardial Mechanics and Valvular and Vascular Abnormalities in Cardiac Amyloidosis.

Nemes A J Clin Med. 2024; 13(15).

PMID: 39124597 PMC: 11313348. DOI: 10.3390/jcm13154330.


Amyloid and collagen templates in aortic valve calcification.

Jayaraman S, Narula N, Narula J, Gursky O Trends Mol Med. 2024; 30(11):1010-1019.

PMID: 38845326 PMC: 11563925. DOI: 10.1016/j.molmed.2024.04.015.

References
1.
Nadlonek N, Lee J, Reece T, Weyant M, Cleveland Jr J, Meng X . Interleukin-1 Beta induces an inflammatory phenotype in human aortic valve interstitial cells through nuclear factor kappa Beta. Ann Thorac Surg. 2013; 96(1):155-62. PMC: 3833085. DOI: 10.1016/j.athoracsur.2013.04.013. View

2.
Greenberg H, Zhao G, Shah A, Zhang M . Role of oxidative stress in calcific aortic valve disease and its therapeutic implications. Cardiovasc Res. 2021; 118(6):1433-1451. PMC: 9074995. DOI: 10.1093/cvr/cvab142. View

3.
Gillmore J, Lovat L, Persey M, Pepys M, Hawkins P . Amyloid load and clinical outcome in AA amyloidosis in relation to circulating concentration of serum amyloid A protein. Lancet. 2001; 358(9275):24-9. DOI: 10.1016/S0140-6736(00)05252-1. View

4.
Kristen A, Schnabel P, Winter B, Helmke B, Longerich T, Hardt S . High prevalence of amyloid in 150 surgically removed heart valves--a comparison of histological and clinical data reveals a correlation to atheroinflammatory conditions. Cardiovasc Pathol. 2009; 19(4):228-35. DOI: 10.1016/j.carpath.2009.04.005. View

5.
Dorbala S, Ando Y, Bokhari S, Dispenzieri A, Falk R, Ferrari V . ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI Expert Consensus Recommendations for Multimodality Imaging in Cardiac Amyloidosis: Part 1 of 2-Evidence Base and Standardized Methods of Imaging. Circ Cardiovasc Imaging. 2021; 14(7):e000029. DOI: 10.1161/HCI.0000000000000029. View